In addition, that LETX-VI treatment of PC12 cells prevented the abnormal accumulation of α-synuclein also suggests that LETX-VI could exert neuroprotectve action by avoiding or reducing neuron injury caused by excessive α-synuclein, which was supported by the in vivo expriments using the PD mouse model. The gene discussed is SNCA; the disease is Parkinson disease.